Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$73.30 USD

73.30
7,219,345

+1.66 (2.32%)

Updated Jul 17, 2024 04:00 PM ET

After-Market: $73.43 +0.13 (0.18%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Biotech Stock Roundup: GILD's Drug News, NVAX & MRNA COVID-19 Vaccine Updates

Regulatory and pipeline updates from Gilead (GILD) and Moderna (MRNA) are a few key highlights from the biotech sector during the past week.

Gilead (GILD) Announces Positive Data on Breast Cancer Drug

Gilead (GILD) breast cancer drug Trodelvy improves overall survival in pre-treated HR+/HER2- metastatic breast cancer patients. The company will also acquire the remaining rights to the drug.

Is VanEck Morningstar Wide Moat ETF (MOAT) a Strong ETF Right Now?

Smart Beta ETF report for MOAT

Gilead (GILD) Q2 Earnings & Sales Top, Revenue Outlook Upped

Gilead (GILD) reports better-than-expected second quarter results on strong HIV business. The company also raises its annual revenue guidance.

Should VanEck Morningstar Wide Moat ETF (MOAT) Be on Your Investing Radar?

Style Box ETF report for MOAT

Gilead Sciences (GILD) Beats Q2 Earnings and Revenue Estimates

Gilead (GILD) delivered earnings and revenue surprises of 4.64% and 6.55%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Is a Beat in Store for BioNTech (BNTX) This Earnings Season?

On BioNTech's (BNTX) second-quarter earnings call, investors are expected to focus on the sales performance of its COVID-19 vaccine, Comirnaty, developed in partnership with Pfizer.

Drug, Biotech Stocks' Q2 Earnings on Aug 2: GILD, INCY & More

Let's check out how the four pharma/drug/biotech companies are placed before the quarterly earnings release on Aug 2.

Viatris (VTRS) to Report Q2 Earnings: What's in the Cards?

Investors will focus on top-line and bottom-line numbers when Viatris (VTRS) reports second-quarter results.

Exelixis (EXEL) to Post Q2 Earnings: What is in the Cards?

Investors will likely focus on the demand for Cabometyx and pipeline updates when Exelixis (EXEL) reports Q2 results. Operating expenses might have jumped.

Novo Nordisk (NVO) to Report Q2 Earnings: What's in the Cards?

Novo Nordisk's (NVO) top line is likely to have been driven by sales of its Diabetes and Obesity Care products in the second quarter of 2022.

Is a Surprise Coming for Gilead Sciences (GILD) This Earnings Season?

Gilead Sciences (GILD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

What is in Store for Regeneron (REGN) This Earnings Season?

Regeneron's (REGN) second-quarter earnings might have gotten a boost from the solid performance of Eylea and Dupixent.

Is a Beat in Store for Gilead (GILD) in This Earnings Season?

Investors will focus on the HIV franchise's performance and Veklury sales in Gilead's (GILD) second-quarter 2022 results.

Biotech Stock Roundup: BMY, BIIB's Q2 Earnings, GILD's Updates & More

Earnings updates from Bristol Myers (BMY) and Biogen (BIIB) are a few key highlights from the biotech sector during the past week.

Will AstraZeneca (AZN) Deliver a Beat This Earnings Season?

Strong demand trends for AstraZeneca's (AZN) key drugs, Lynparza, Tagrisso, Imfinzi and Farxiga are likely to have driven the top line in the second quarter.

Earnings Preview: Bionano Genomics, Inc. (BNGO) Q2 Earnings Expected to Decline

Bionano Genomics, Inc. (BNGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Gilead Sciences (GILD) Stock Moves -0.21%: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $60.62, moving -0.21% from the previous trading session.

Neena Mishra headshot

Should You Buy Beaten-Down Biotech Stocks & ETFs?

We highlight 4 ETFs that have started rebounding after a brutal sell-off

Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Gilead (GILD) Gets Positive CHMP Opinion for Veklury & Tecartus

Gilead (GILD) receives positive CHMP opinion for full marketing authorization of its COVID-19 Jab, Veklury, and for using its CAR-T cell therapy Tecartus to treat relapsed or refractory B-cell precursor ALL in adults.

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

Gilead Sciences (GILD) closed at $61.55 in the latest trading session, marking a -0.92% move from the prior day.

Should You Invest in the VanEck Biotech ETF (BBH)?

Sector ETF report for BBH

Humanigen (HGEN) Plunges as COVID Study Fails to Meet Goal

The NIAID's ACTIV-5/BET-B study evaluating Humanigen's (HGEN) lenzilumab plus remdesivir in hospitalized COVID-19 patients fails to meet the primary endpoint. Stock down.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

Smart Beta ETF report for IBB